
    
      The study inclusion criteria is patients with main trunk (VSM, SSV, AASV) reflux to be
      treated with EVLA, suffering C2-C3 varicose disease, age 18-years and no severe
      co-morbidities.

      Patients with written consent will be randomized to two primary treatments groups; EVLA only
      and EVLA combined with sclerotherapy of varicose tributaries. The primary outcome is the
      requirement additional sclerotherapy on 3 month control visit. Other study outcomes are pain,
      quality of life (veins questionnaire), severity score and also recurring of varicose disease
      at 1, 3 and 5 years.
    
  